닥시보툴리눔톡신A-란(닥시파이™): 종합적인 개요- 장시간 보톡스

<a href="https://www.skintherapyletter.com/cosmetic-dermatology/daxibotulinumtoxina-lanm-daxxify/" target="_top" class="ke-link">DaxibotulinumtoxinA-lanm (Daxxify™): A Comprehensive Overview (skintherapyletter.com)</a><div class="figure-open" contenteditable="false" data-ke-type="opengraph" data-ke-align="alignCenter" data-og-type="website" data-og-title="DaxibotulinumtoxinA-lanm (Daxxify™): A Comprehensive Overview" data-og-description="DaxibotulinumtoxinA-lanm (Daxxify™) increases its efficacy and safety as a botulinum toxin A (BoNTA) for treating facial lines." data-og-host="www.skintherapyletter.com" data-og-source-url="https://www.skintherapyletter.com/cosmetic-dermatology/daxibotulinumtoxina-lanm-daxxify/" data-og-url="https://www.skintherapyletter.com/cosmetic-dermatology/daxibotulinumtoxina-lanm-daxxify/" data-og-image="https://scrap.kakaocdn.net/dn/W77Fm/hyTjSVb01o/fEgQQvWyujnFWl83nLZOF1/img.jpg?width=1000&height=470&face=0_0_1000_470,https://scrap.kakaocdn.net/dn/bRqQP3/hyTjQiL82F/Yw1gUzE0J2f4lgAWdLStp1/img.jpg?width=1000&height=470&face=0_0_1000_470"><a href="https://www.skintherapyletter.com/cosmetic-dermatology/daxibotulinumtoxina-lanm-daxxify/" target="_blank" data-source-url="https://www.skintherapyletter.com/cosmetic-dermatology/daxibotulinumtoxina-lanm-daxxify/"><div class="og-image"><img src="https://scrap.kakaocdn.net/dn/W77Fm/hyTjSVb01o/fEgQQvWyujnFWl83nLZOF1/img.jpg?width=1000&height=470&face=0_0_1000_470,https://scrap.kakaocdn.net/dn/bRqQP3/hyTjQiL82F/Yw1gUzE0J2f4lgAWdLStp1/img.jpg?width=1000&height=470&face=0_0_1000_470" alt="" xxxxonerror="this.src="//img1.kakaocdn.net/thumb/C200x200/?fname=https%3A%2F%2Ft1.daumcdn.net%2Fcafe_image%2Fcafe_meta_image_190529.png""></div><div class="og-text">DaxibotulinumtoxinA-lanm (Daxxify™): A Comprehensive OverviewDaxibotulinumtoxinA-lanm (Daxxify™) increases its efficacy and safety as a botulinum toxin A (BoNTA) for treating facial lines.www.skintherapyletter.com</div></a></div>출처: <a href="https://pubmed.ncbi.nlm.nih.gov/37440610/" target="_blank" class="ke-link">https://pubmed.ncbi.nlm.nih.gov/37440610/</a> Skin Therapy Lett . 2023 Jul;28(4):1-3. DaxibotulinumtoxinA-lanm (Daxxify™): A Comprehensive Overview닥시보툴리눔톡신A-란(닥시파이™): 종합적인 개요 - 22년 9월  FDA 공인  <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Salame+N&cauthor_id=37440610" target="_top" class="ke-link">Nicole Salame</a> <a href="https://pubmed.ncbi.nlm.nih.gov/37440610/#full-view-affiliation-1" target="_top" class="ke-link"> 1 </a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Eber+AE&cauthor_id=37440610" target="_top" class="ke-link">Ariel E Eber</a> <a href="https://pubmed.ncbi.nlm.nih.gov/37440610/#full-view-affiliation-2" target="_top" class="ke-link"> 2 </a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Dover+J&cauthor_id=37440610" target="_top" class="ke-link">Jeffrey Dover</a> <a href="https://pubmed.ncbi.nlm.nih.gov/37440610/#full-view-affiliation-3" target="_top" class="ke-link"> 3 </a>  AbstractBotulinum toxin A (BoNTA) is produced by Clostridium botulinum and widely used for aesthetic indications requiring neuromuscular blockade. For dynamic facial lines, BoNTA is effective and safe, but also temporary, requiring repeat injections approximately every 3-4 months for maintenance of effects. There is a desire by both patients and providers for a longer-lasting neurotoxin to prevent periods of suboptimal correction.초록 보툴리눔 독소 A(BoNTA)는 클로스트리디움 보툴리눔에 의해 생성되며 신경근 차단이 필요한 미용 적응증에 널리 사용됩니다. 역동적인 얼굴 라인에 효과적이고 안전하지만 일시적이기 때문에 효과 유지를 위해 약 3~4개월마다 반복 주사를 맞아야 하는 단점이 있습니다. 환자와 의료진 모두 최적의 교정이 이루어지지 않는 기간을 방지하기 위해 더 오래 지속되는 신경독소에 대한 열망이 있습니다.  Approved by the US Food and Drug Administration (FDA) in September 2022, daxibotulinumtoxinA for injection (DAXI or Daxxify™) is the first long-lasting BoNTA formulated with a 150-kDa BoNTA (RTT150) and proprietary stabilizing excipient peptide (RTP004) in place of human serum albumin. DAXI is approved for treatment of moderate to severe glabellar lines. The median duration of effect was 6 months and results lasted as long as 9 months in some patients. Its unique formulation and prolonged effectiveness positions DAXI as a safe, novel BoNTA for improved durability and patient satisfaction.2022년 9월 미국 식품의약국(FDA)의 승인을 받은 주사용 닥시보툴리눔톡신A(DAXI 또는 닥시파이프™)는 인간 혈청 알부민 대신 150-kDa BoNTA(RTT150)와 독점 안정화 부형제 펩타이드(RTP004)로 제조된 최초의 오래 지속되는 BoNTA입니다. DAXI는 중등도에서 중증의 미간주름 치료제로 승인되었습니다. 효과 지속 기간의 중앙값은 6개월이었으며 일부 환자에서는 9개월까지 효과가 지속되었습니다. 독특한 제형과 장기간 지속되는 효과로 인해 DAXI는 지속성과 환자 만족도를 개선한 안전하고 새로운 BoNTA로 자리매김했습니다.